Bicara Therapeutics Stock Target Price and Analyst Consensus
| BCAX Stock | 16.91 0.32 1.93% |
The current analyst and expert consensus on Bicara Therapeutics is Strong Buy, with 4 strong buy opinions. The current projected Bicara Therapeutics target price consensus is 30.78 with 7 analyst opinions. Check out Macroaxis Advice on Bicara Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. The most common way Bicara Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Bicara Therapeutics executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Bicara Therapeutics. We strongly encourage you to use your own analysis of Bicara Therapeutics to validate this buy or sell advice. Bicara Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Bicara Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 3.8054.
Lowest Forecast 28.01 | Highest Forecast 34.16 | Target Price 30.78 |
It's important to approach Bicara Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Bicara Therapeutics Target Price Consensus
Bicara target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Bicara Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Strong Buy |
Most Bicara analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Bicara stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Bicara Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBicara Therapeutics Target Price Projection
Bicara Therapeutics' current and average target prices are 16.91 and 30.78, respectively. The current price of Bicara Therapeutics is the price at which Bicara Therapeutics Common is currently trading. On the other hand, Bicara Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Bicara Therapeutics Market Quote on 29th of January 2026
Target Price
Analyst Consensus On Bicara Therapeutics Target Price
Bicara Therapeutics Analyst Ratings
Bicara Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Bicara Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Bicara Therapeutics' financials, market performance, and future outlook by experienced professionals. Bicara Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Bicara Therapeutics price targets
Bicara Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Bicara Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Bicara Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Bicara Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Bicara Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Bicara Therapeutics is a key component of Bicara Therapeutics valuation and have some predictive power on the future returns of a Bicara Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Index Invested over 40 shares | |
 | Hedge Favorites Invested over 30 shares | |
 | Momentum Invested over 30 shares | |
 | FinTech Invested over 50 shares | |
 | Impulse Invested over 200 shares | |
 | Cash Cows Invested few shares | |
 | Advertising Invested few shares | |
 | Climate Change Invested over 90 shares | |
 | Technology Invested few shares | |
 | Investor Favorites Invested few shares | |
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.